U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358884) titled 'First in Human Study of QLS5316 in Solid Tumors' on Jan. 05.
Brief Summary: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Colorectal Cancer
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Intervention:
DRUG: QLS5316
Varying doses of QLS5316
Recruitment ...